Clinical trials: Placebo-Post
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and…
- Trial name
- NCT02347085
- Testing
- GFF MDI (PT003)
- Volunteers
- 43 people
- Sponsor
- Pearl Therapeutics, Inc.
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Hallux Valgus
Continuous Wound Infiltration After Hallux Valgus Surgery
The aim of this study is to investigate the effect of continuous wound infiltration with ropivacaine in comparison to standard pain management after elective distal metatarsal osteotomy for postoperative pain control.
- Trial name
- CWI-HVS (NCT02182999)
- Testing
- Wound infiltration catheter, NaCl 0.9%, Ropivacaine 0.2%
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University Innsbruck
Node Positive HER2 Negative Breast Cancer
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy…
- Trial name
- NCT02927249
- Testing
- Aspirin
- Where
- 1,452 sites in United States, Canada and 2 more
- Volunteers
- 3,021 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malaria, Malaria,Falciparum
A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI
USSPZV7 is a randomized, phase 1, double-blind, placebo-controlled trial of Sanaria® PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity, and vaccine…
- Trial name
- NCT05604521
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Posttraumatic Stress Disorder
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least severe PTSD. The main question it aims to answer is: Do three sessions of MDMA-assisted therapy reduce PTSD…
- Trial name
- NCT03537014
- Testing
- Therapy, midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Resilient Pharmaceuticals
Group B Streptococcal Infection
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
This is a phase II, multicentre, multinational, randomized, parallel group, placebo-controlled study of four vaccination regimens in healthy pregnant women.
- Trial name
- NCT05154578
- Testing
- GBS-NN/NN2 Vaccine
- Where
- 10 sites in Denmark, South Africa and 1 more
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Stress Disorders, Post-Traumatic, Combat Disorders
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
The purpose of this study is to determine whether prazosin will: reduce the incidence of nightmares and sleep disturbance increase functioning and sense of well being in combat-trauma exposed Operation Iraqi Freedom/Operation…
- Conditions
- Stress Disorders, Post-Traumatic, Combat Disorders, Sleep Disorders
- Trial name
- NCT00990106
- Testing
- prazosin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Post-Operative Ileus
Asimadoline for the Treatment of Post-Operative Ileus
The purpose of this study is to evaluate the safety and efficacy of asimadoline in patients who have undergone a laparoscopic segmental colectomy and determine whether it reduces the time to recovery of bowel function compared to…
- Trial name
- NCT00443040
- Testing
- Asimadoline
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tioga Pharmaceuticals
Wounds
Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation
Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.
- Trial name
- NCT00656474
- Testing
- GLYC-101 gel (1.0 %)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- TR Therapeutics
Colorectal Adenoma, Colorectal Carcinoma
Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
The purpose of this study is to assess how effective celecoxib is in limiting production of a hormone, prostaglandin, in the subject's body.
- Trial name
- UAB0040 (NCT00582660)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Anesthesia, General
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)
The objective of this trial was to establish the dose-response of T2 (the amplitude of the first response of second twitch to train of four (TOF) stimulation, expressed as percentage of control first twitch,T1) in Japanese and…
- Trial name
- NCT00591409
- Testing
- sugammadex
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Posttraumatic Stress Disorder
Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
This pilot study gathered preliminary evidence of the safety and efficacy of four potencies of smoked cannabis to manage chronic, treatment-resistant PTSD among veterans: (1) High THC/ Low CBD (High THC), (2) Low THC/High CBD…
- Trial name
- NCT02759185
- Testing
- High THC cannabis, High CBD cannabis, THC/CBD cannabis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Multidisciplinary Association for Psychedelic Studies
Acute Decompensated Heart Failure
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
- Trial name
- NCT04318093
- Testing
- BMS-986259
- Where
- 18 sites in Argentina, Czechia and 4 more
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Asthma
Induced Sputum Study (0000-065)
The primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation.
- Trial name
- NCT00623714
- Testing
- Comparator: fluticasone
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Wounds
Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation
The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide…
- Trial name
- NCT00792688
- Testing
- GLYC-101 Gel (0.1%), GLYC-101 Gel (1.0%)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- TR Therapeutics
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd